CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment

European Neuropsychopharmacology

Volumn 25, Issue 8, 2015, Pages 1091-1098

  Rolstad, Sindre ^a   Jakobsson, Joel ^a   Sellgren, Carl ^b   Isgren, Anniella ^a   Ekman, Carl Johan ^b   Bjerke, Maria ^a   Blennow, Kaj ^a   Zetterberg, Henrik ^a,c   Pålsson, Erik ^a   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Cerebrospinal fluid; Inflammation; Neuropsychology

Indexed keywords

BIOLOGICAL MARKER; UNCLASSIFIED DRUG; YKL 40; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; COGNITION; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGY; STATISTICAL MODEL;

ADIPOKINES; ADULT; BIOMARKERS; BIPOLAR DISORDER; COGNITION; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; LECTINS; LINEAR MODELS; MALE; NEUROPSYCHOLOGICAL TESTS;

EID: 84938751882     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.04.023     Document Type: Article

References (48)

1. Arnone D., Cavanagh J., Gerber D., Lawrie S.M., Ebmeier K.P., McIntosh A.M. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br. J. Psychiatry 2009, 195(3):194-201. the journal of mental science.
2. Association A.P. Diagnostic and Statistical Manual of Mental Disorders 2000, DSM-IV-TR®, American Psychiatric Association. fourth edition.
3. Bearden C.E., Shih V.H., Green M.F., Gitlin M., Sokolski K.N., Levander E., Marusak S., Hammen C., Sugar C.A., Altshuler L.L. The impact of neurocognitive impairment on occupational recovery of clinically stable patients with bipolar disorder: a prospective study. Bipolar Disord. 2011, 13(4):323-333.
4. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhaes P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35(3):804-817.
5. Berman A.H., Bergman H., Palmstierna T., Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur. Addict Res. 2005, 11(1):22-31.
6. Bjerke M., Zetterberg H., Edman A., Blennow K., Wallin A., Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J. Alzheimer's Dis.: JAD 2011, 27(3):665-676.
7. Bora E., Yucel M., Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 2009, 113(1-2):1-20.
8. Bourne C., Aydemir O., Balanza-Martinez V., Bora E., Brissos S., Cavanagh J.T., Clark L., Cubukcuoglu Z., Dias V.V., Dittmann S., Ferrier I.N., Fleck D.E., Frangou S., Gallagher P., Jones L., Kieseppa T., Martinez-Aran A., Melle I., Moore P.B., Mur M., Pfennig A., Raust A., Senturk V., Simonsen C., Smith D.J., Bio D.S., Soeiro-de-Souza M.G., Stoddart S.D., Sundet K., Szoke A., Thompson J.M., Torrent C., Zalla T., Craddock N., Andreassen O.A., Leboyer M., Vieta E., Bauer M., Worhunsky P.D., Tzagarakis C., Rogers R.D., Geddes J.R., Goodwin G.M. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr. Scand. 2013, 128(3):149-162.
9. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 2010, 1803(1):55-71.
10. Bryant-Comstock L., Stender M., Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002, 4(6):398-405.
11. Canto E., Tintore M., Villar L.M., Costa C., Nurtdinov R., Alvarez-Cermeno J.C., Arrambide G., Reverter F., Deisenhammer F., Hegen H., Khademi M., Olsson T., Tumani H., Rodriguez-Martin E., Piehl F., Bartos A., Zimova D., Kotoucova J., Kuhle J., Kappos L., Garcia-Merino J.A., Sanchez A.J., Saiz A., Blanco Y., Hintzen R., Jafari N., Brassat D., Lauda F., Roesler R., Rejdak K., Papuc E., de Andres C., Rauch S., Khalil M., Enzinger C., Galimberti D., Scarpini E., Teunissen C., Sanchez A., Rovira A., Montalban X., Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015, 138(Pt 4):918-931. a journal of neurology.
12. Comabella M., Fernandez M., Martin R., Rivera-Vallve S., Borras E., Chiva C., Julia E., Rovira A., Canto E., Alvarez-Cermeno J.C., Villar L.M., Tintore M., Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133(Pt 4):1082-1093. a journal of neurology.
13. Craig-Schapiro R., Perrin R.J., Roe C.M., Xiong C., Carter D., Cairns N.J., Mintun M.A., Peskind E.R., Li G., Galasko D.R., Clark C.M., Quinn J.F., D'Angelo G., Malone J.P., Townsend R.R., Morris J.C., Fagan A.M., Holtzman D.M. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol. Psychiatry 2010, 68(10):903-912.
14. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm. 2006, 113(11):1685-1695.
15. Ekman M., Granstrom O., Omerov S., Jacob J., Landen M. The societal cost of bipolar disorder in Sweden. Soc. Psychiatry Psychiatr. Epidemiol 2013.
16. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70(8):1078-1090.
17. Hjalmarsson C., Bjerke M., Andersson B., Blennow K., Zetterberg H., Aberg N.D., Olsson B., Eckerstrom C., Bokemark L., Wallin A. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J. Cent. Nerv. Syst. Dis. 2014, 6:51-58.
18. Hoshi T., Yamagami H., Furukado S., Miwa K., Tanaka M., Sakaguchi M., Sakoda S., Kitagawa K. Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors. Eur. J. Neurol. 2010, 17(9):1134-1140. the official journal of the European Federation of Neurological Societies.
19. Huang T.L., Lin F.C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(2):370-372.
20. Jakobsson J., Bjerke M., Sahebi S., Isgren A., Ekman C., Sellgren C., Olsson B., Zetterberg H., Blennow K., Pålsson E., Landén M. J. Psychiatry Neurosci. 2015, 40(2):14018.
21. Jakobsson J., Zetterberg H., Blennow K., Johan Ekman C., Johansson A., Landén M. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 2013, 38(4):664-672. official publication of the American College of Neuropsychopharmacology.
22. Johansen J.S., Stoltenberg M., Hansen M., Florescu A., Horslev-Petersen K., Lorenzen I., Price P.A. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999, 38(7):618-626.
23. Lautner R., Mattsson N., Scholl M., Augutis K., Blennow K., Olsson B., Zetterberg H. Biomarkers for microglial activation in Alzheimer's disease. Int. J. Alzheimer's Dis. 2011, 2011:939426.
24. Lezak M., Howieson D., Bigler E., Tranel D. Neuropsychological Assessment 2012, Oxford University Press, USA.
25. Lively S., Schlichter L.C. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J. Neuroinflamm. 2013, 10:75.
26. Lorenzl S., Albers D.S., LeWitt P.A., Chirichigno J.W., Hilgenberg S.L., Cudkowicz M.E., Beal M.F. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 2003, 207(1-2):71-76.
27. Mackinnon D.P., Dwyer J.H. Estimating mediated effects in prevention studies. Eval. Rev. 1993, 17(2):144-158.
28. Maier B., Laurer H.L., Rose S., Buurman W.A., Marzi I. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J. Neurotrauma 2005, 22(7):822-835.
29. Malmestrom C., Axelsson M., Lycke J., Zetterberg H., Blennow K., Olsson B. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J. Neuroimmunol. 2014, 269(1-2):87-89.
30. Merikangas K.R., Jin R., He J.P., Kessler R.C., Lee S., Sampson N.A., Viana M.C., Andrade L.H., Hu C., Karam E.G., Ladea M., Medina-Mora M.E., Ono Y., Posada-Villa J., Sagar R., Wells J.E., Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry 2011, 68(3):241-251.
31. Modvig S., Degn M., Roed H., Sorensen T., Larsson H., Langkilde A., Frederiksen J., Sellebjerg F. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Multiple Scler 2015.
32. Mora E., Portella M.J., Forcada I., Vieta E., Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. Psychol. Med. 2013, 43(6):1187-1196.
33. Mur M., Portella M.J., Martinez-Aran A., Pifarre J., Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J. Clin. Psychiatry 2008, 69(5):712-719.
34. Ostergaard C., Johansen J.S., Benfield T., Price P.A., Lundgren J.D. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin. Diagn. Lab. Immunol. 2002, 9(3):598-604.
35. Palsson E., Figueras C., Johansson A.G., Ekman C.J., Hultman B., Ostlind J., Landen M. Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls. BMC Psychiatry 2013, 13:165.
36. Phillips M.L., Kupfer D.J. Bipolar disorder diagnosis: challenges and future directions. Lancet 2013, 381(9878):1663-1671.
37. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15(4):384-392.
38. Recklies A.D., Ling H., White C., Bernier S.M. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J. Biol. Chem. 2005, 280(50):41213-41221.
39. Renkema G.H., Boot R.G., Au F.L., Donker-Koopman W.E., Strijland A., Muijsers A.O., Hrebicek M., Aerts J.M. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem./FEBS 1998, 251(1-2):504-509.
40. Robinson L.J., Ferrier I.N. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006, 8(2):103-116.
41. Robinson L.J., Thompson J.M., Gallagher P., Goswami U., Young A.H., Ferrier I.N., Moore P.B. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J. Affect. Disord. 2006, 93(1-3):105-115.
42. Rolstad S., Berg A.I., Bjerke M., Blennow K., Johansson B., Zetterberg H., Wallin A. Amyloid-beta(4)(2) is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J. Alzheimer's Dis.: JAD 2011, 26(1):135-142.
43. Rolstad S., Berg A.I., Bjerke M., Johansson B., Zetterberg H., Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J. Alzheimer's Dis.: JAD 2013, 34(4):949-956.
44. Ryden E., Thase M.E., Straht D., Aberg-Wistedt A., Bejerot S., Landen M. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr. Scand. 2009, 120(3):239-246.
45. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., Lavori P., Lebowitz B., Rudorfer M., Frank E., Nierenberg A.A., Fava M., Bowden C., Ketter T., Marangell L., Calabrese J., Kupfer D., Rosenbaum J.F. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 2003, 53(11):1028-1042.
46. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption -II. Addiction 1993, 88(6):791-804.
47. Savitz J., Solms M., Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord. 2005, 7(3):216-235.
48. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.